Preclinical testing of the Akt inhibitor triciribine in T‐cell acute lymphoblastic leukemia
- 20 September 2010
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 226 (3) , 822-831
Abstract
Over the past 20 years, survival rates of T‐cell acute lymphoblastic leukemia (T‐ALL) patients have improved, mainly because of advances in polychemotherapy protocols. Despite these improvements, we still need novel and less toxic treatment strategies targeting aberrantly activated signaling networks which increase proliferation, survival, and drug resistance of T‐ALL cells. One such network is represented by the phosphatidylinositol 3‐kinase (PI3K)/Akt axis. PI3K inhibitors have displayed some promising effects in preclinical models of T‐ALL. Here, we have analyzed the therapeutic potential of the Akt inhibitor, triciribine, in T‐ALL cell lines. Triciribine caused cell cycle arrest and caspase‐dependent apoptosis. Western blots demonstrated a dose‐dependent dephosphorylation of Akt1/Akt2, and of mammalian target of rapamycin complex 1 downstream targets in response to triciribine. Triciribine induced autophagy, which could be interpreted as a defensive mechanism, because an autophagy inhibitor (chloroquine) increased triciribine‐induced apoptosis. Triciribine synergized with vincristine, a chemotherapeutic drug employed for treating T‐ALL patients, and targeted the side population of T‐ALL cell lines, which might correspond to leukemia initiating cells. Our findings indicate that Akt inhibition, either alone or in combination with chemotherapeutic drugs, may serve as an efficient treatment towards T‐ALL cells requiring upregulation of this signaling pathway for their proliferation and survival. J. Cell. Physiol. 226: 822–831, 2011.Keywords
This publication has 42 references indexed in Scilit:
- The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membraneCell Death & Differentiation, 2010
- Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signallingBritish Journal of Cancer, 2010
- Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapyCancer and Metastasis Reviews, 2010
- mTOR regulation of autophagyFEBS Letters, 2010
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology GroupLeukemia, 2009
- PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like CellsCell Stem Cell, 2009
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsDrug Resistance Updates, 2008
- Autophagy in the Pathogenesis of DiseaseCell, 2008